Circumcision reduces the risk of HIV infection in heterosexual US men

December 17, 2008

A new U.S. study has found that being circumcised significantly reduced the risk of HIV infection in heterosexual African American men known to have been exposed to the virus. The findings complement those of recently reported clinical trials in Africa, where interventional use of adult male circumcision similarly reduced the risk of HIV infection in heterosexual men. The findings of the new study, along with similar results from other studies, suggest that circumcision may protect other heterosexual males in the U.S. The promising new findings are reported in the January 1 issue of The Journal of Infectious Diseases, now available online.

Lee Warner, PhD, MPH, and colleagues at the Centers for Disease Control and Prevention (CDC) and the Johns Hopkins University School of Medicine studied the records of more than 26,000 African American men who had had HIV testing during visits to two Baltimore, Maryland, STD clinics from 1993 to 2000. The subjects selected for the study said that they did not inject drugs and had sex only with women. Their visits to the clinics were classified as involving known HIV exposure if there had been a recent notification of such exposure by a sex partner or by a clinic's disease intervention specialists; clinic visits for other reasons were classified as involving unknown HIV exposure. By these criteria, the investigators found 394 visits with known exposure and 40,177 visits with unknown exposure.

In visits by men with known HIV exposure, being circumcised was associated with a 51 percent reduction in HIV prevalence (10.2 percent of circumcised men vs. 22.0 percent of uncircumcised men). In contrast, HIV prevalence did not significantly differ in circumcised compared to uncircumcised men with unknown HIV exposure (2.5 percent vs 3.3 percent).

The investigators noted that three other U.S.-based studies had previously suggested that circumcision may be associated with reduced HIV risk, but the findings were limited by small sample size or extremely low HIV prevalence and did not achieve statistical significance. Indeed, HIV prevalence in the United States is very low (about 0.4 percent), and the proportion of circumcised adult males is high (about 80 percent), which could make it hard for conventional observational studies (i.e., studies that are not clinical trials) to discern whether circumcision actually has a protective effect. By focusing on patients who had documented exposure to an HIV-infected female partner, the current study was able to reveal that there was indeed a protective effect. This approach, the investigators said, "represents a significant methodological advancement over most previous observational studies."

In a separate editorial on the topic, Ronald H. Gray, MBBS, MSc, of Johns Hopkins University, pointed out that circumcision may be especially important for minority U.S. populations, including Hispanic as well as African American men--subgroups most at risk for HIV infection. He also noted that the American Academy of Pediatrics has thus far not recommended routine neonatal circumcision, and that Medicaid does not cover the procedure. "It is to be hoped," he said, "that the paper by Warner et al., in conjunction with the weight of evidence from international studies, will persuade the Academy to recognize the public health importance of this surgery for prevention of HIV in minority U.S. populations."

Fast Facts:
-end-
Founded in 1904, The Journal of Infectious Diseases is the premier publication in the Western Hemisphere for original research on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune mechanisms. Articles in JID include research results from microbiology, immunology, epidemiology, and related disciplines. JID is published under the auspices of the Infectious Diseases Society of America (IDSA). Based in Arlington, Va., IDSA is a professional society representing more than 8,600 physicians and scientists who specialize in infectious diseases. Nested within the IDSA, the HIV Medicine Association (HIVMA) is the professional home for more than 3,600 physicians, scientists and other health care professionals dedicated to the field of HIV/AIDS. HIVMA promotes quality in HIV care and advocates policies that ensure a comprehensive and humane response to the AIDS pandemic informed by science and social justice. For more information, visit www.idsociety.org and www.hivma.org.

Infectious Diseases Society of America

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.